EPIC SCIENCES DEVELOPS NOVEL LIQUID BIOPSY DIAGNOSTICS TO PERSONALIZE AND ADVANCE THE TREATMENT OF CANCER

VISIT US AT BOOTH 2066
ABSTRACT 3050 | POSTER 42
Title: CTC vs. biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts)
Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Howard I. Scher, Memorial Sloan Kettering Cancer Center

ABSTRACT 5075 | POSTER 187
Title: Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC)
Poster Session: Genitourinary (Prostate) Cancer
Howard I. Scher, Memorial Sloan Kettering Cancer Center

ABSTRACT 5065 | POSTER 177
Title: SLFN11 expression in advanced prostate cancer (APC) predicts response to platinum-based chemotherapy (PLT)
Poster session: Genitourinary (Prostate) Cancer
Vincenza Conteduca, M.D., Ph.D., Dana Farber Cancer Institute

ABSTRACT TPS5086 | POSTER 198a
Title: Pamiparib, an investigational PARP inhibitor in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.
Poster session: Genitourinary (Prostate) Cancer
Simon Chowdhury, M.D., Guy’s, King’s and St. Thomas’ Hospitals, and Sarah Cannon Research Institute
Title: Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivolpi)

Poster Session: Genitourinary (Nonprostate) Cancer

Andrea B. Apolo, M.D., Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH
A R - V 7

A RARE LEVEL OF CONFIDENCE

Virtually all men with metastatic prostate cancer will eventually develop mCRPC, an advanced stage of the disease. The AR-V7 test is the first and only Medicare reimbursed clinically-validated predictive CTC liquid biopsy test for mCRPC.

NO CELL LEFT BEHIND™

Our radically different approach is bias-free, a unique rare cell detection engine that can capture, identify and characterize all the circulating tumor cells (CTCs) in a blood sample and see the cancer cells that others miss. The insights gained empower physicians to select the path to confident treatment decisions, targeted for the individual patient, in less time.

AVAILABLE EXCLUSIVELY THROUGH GENOMIC HEALTH IN THE US

VISIT OUR COMMERCIAL PARTNER GENOMIC HEALTH AT BOOTH 12097 TO LEARN MORE!

All tests are performed by Epic Sciences at our centralized, CAP accredited and CLIA-certified laboratory in San Diego, California.